- Home
- News
- latamerica
- molecule generator
Molecule Generator Articles & Analysis
16 news found
“The mechanism of action of ATG-037 in inhibiting adenosine-generating CD73 is expected to reverse an immunosuppressed tumor microenvironment, thereby creating potential additive benefit with multiple immuno-oncological approaches. ...
With the combined acquisitions of CellPoint and AboundBio announced earlier this year, we positioned ourselves in the cell therapy space, combining the potentially disruptive manufacturing and delivery model of CellPoint (Lonza’s Cocoon®, a closed, automated manufacturing platform for cell therapy) with the ability to develop next-generation CAR-Ts, small ...
ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies in Australia and China, thus becoming the first oral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ...
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ...
Key Takeaways: Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body - just as the advent of next-generation DNA sequencing has revolutionized our knowledge of the human genome over ...
The funds awarded to Orbit will further validate the microfluidic components of Orbit’s peptide discovery platform, resulting in a next-generation microfluidic-based functional screen capable of interrogating millions of peptides in cell-based assays. ...
Insilico's PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico's AI platform. The compound can be efficiently prepared with a two-step synthesis from commercial starting materials. ...
We believe the promise of better outcomes for patients treated with these multi-specific antibodies represents a next generation of large molecule therapeutics and the next chapter of OPKO,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. ...
"Powered by AI, the MAT2A program team was able to discover the PCC molecule with high selectivity of MTAP-deleted cancer cells over wide-type cells, which we believe provides key differentiation compared to reported MAT2A inhibitors," said Feng Ren, PhD, Chief Scientific Officer of Insilico Medicine. "This is the second PCC in our growing synthetic lethality pipeline, and we are ...
ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine's end-to-end AI-powered drug discovery platform. ...
Other highlights include: Advancing four AI-discovered programs to the clinic while further growing clinical development capabilities Expanding the AI Workbench from rare, monogenic conditions to more complex, common diseases Generating a large-scale set of opportunities by evaluating one hundred genes to identify novel targets, mechanisms, and preclinical programs that ...
Protein-protein interaction (PPI) is a highly specific physical contact established between two or more protein molecules. It is the result of biochemical events generated by the interaction, including electrostatic force, hydrogen bonding, and hydrophobic interaction. Many are physical contacts of molecular associations between chains that occur in cells or ...
When enzymes are conjugated to other molecules, they act as signal generators. Several reporter enzymes, including horseradish peroxidase (HRP), alkaline phosphatase (AP), and others, can be linked to antibodies, proteins, and nucleic acids for use in immunoassays and biosensors. ...
Sibylla PPI-FIT technology identifies novel druggable pockets in the intermediate folding states of proteins Sibylla intends to market the PPI-FIT technology platform-as-a-service‚ to the biotechnology and pharmaceutical industries. It also plans to generate its own in-house proprietary pipeline Verona (Italy), May 18th 2021 – Sibylla Biotech announced a research ...
Last September Insilico Medicine published a landmark paper in Nature Biotechnology demonstrating the application of its generative tensorial reinforcement learning systems to generate novel molecules for kinases in just 46 days including experimental validation which was widely covered by the press. ...
Using a new imaging technique, National Institutes of Health researchers have found that the biological machinery that builds DNA can insert molecules into the DNA strand that are damaged as a result of environmental exposures. These damaged molecules trigger cell death that produces some human diseases, according to the researchers. ...